诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据 - 老虎社区

应交易所要求，美/港股行情延时15分钟展示，下载APP即可免费查看实时行情。

关闭

09969 诺诚健华

未开盘 04-16 16:08:30

8.270

-0.250

-2.93%

最高8.440	最低8.090	成交量706.00万
今开8.410	昨收8.520	日振幅4.11%
总市值145.63亿	流通市值123.64亿	总股本17.61亿
成交额5,827万	换手率0.47%	流通股本14.95亿
市净率--	ROE--	每股收益0.00
52周最高--	52周最低--	市盈率--
股息--	股息收益率--	ROA--

数据加载中...

北京优虎网络科技有限公司

免责声明:香港交易所资讯服务有限公司、其控股公司及／或该等控股公司的任何附属公司均竭力确保所提供信息的准确和可靠度，但不能保证其绝对准确和可靠，且亦不会承担因任何不准确或遗漏而引起的任何损失或损害的责任（不管是否侵权法下的责任或合约责任又或其它责任）

{"stockData":{"symbol":"09969","market":"HK","secType":"STK","nameCN":"诺诚健华","latestPrice":8.27,"timestamp":1744790910036,"preClose":8.52,"halted":0,"volume":7060007,"delay":0,"floatShares":1495000000,"shares":1761000000,"eps":-0.2763607157822855,"marketStatus":"未开盘","change":-0.25,"latestTime":"04-16 16:08:30","open":8.41,"high":8.44,"low":8.09,"amount":58270032,"amplitude":0.04108,"askPrice":8.28,"askSize":20000,"bidPrice":8.27,"bidSize":5000,"shortable":3,"etf":0,"ttmEps":-0.2763607157822855,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1744853400000},"marketStatusCode":0,"adr":0,"listingDate":1584892800000,"exchange":"SEHK","adjPreClose":8.52,"openAndCloseTimeList":[[1744767000000,1744776000000],[1744779600000,1744790400000]],"volumeRatio":0.663982,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD","astockBrief":{"symbol":"688428","market":"SH","secType":"STK","nameCN":"诺诚健华","latestPrice":17.64,"timestamp":1744786800000,"preClose":17.98,"halted":0,"volume":4463200,"delay":0,"premium":"-55.89"}},"requestUrl":"/m/hq/s/09969","defaultTab":"news","newsList":[{"id":"2527483732","title":"诺诚健华(09969)新一代泛TRK抑制剂申报上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2527483732","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527483732?lang=zh_cn&edition=full","pubTime":"2025-04-16 21:24","pubTimestamp":1744809887,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，4月16日，诺诚健华(09969)宣布中国国家药品监督管理局(NMPA)药品审评中心(CDE)已受理新一代泛TRK抑制剂Zurletrectinib(ICP-723)用于治疗携带 NTRK融合基因的晚期实体瘤成人和青少年(12周岁≤年龄<18周岁)患者的新药上市申请(NDA)。Zurletrectinib是诺诚健华自主研发的泛TRK抑制剂，不仅能够有效抑制 TRKA、TRKB、TRKC，而且能够有效抑制TRKA的耐药性突变G595R和 G667C等，可以克服第一代TRK抑制剂的获得性耐药。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1279763.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","688428","BK1574","09969","BK0239"],"gpt_icon":0},{"id":"2527299736","title":"诺诚健华、鞍石药业、福泰制药新药多点发力","url":"https://stock-news.laohu8.com/highlight/detail?id=2527299736","media":"医药经济报","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527299736?lang=zh_cn&edition=full","pubTime":"2025-04-16 14:01","pubTimestamp":1744783286,"startTime":"0","endTime":"0","summary":"诺诚健华1类新药申报上市今日，CDE官网显示，已受理诺诚健华新一代泛TRK抑制剂Zurletrectinib用于治疗携带NTRK融合基因的晚期实体瘤成人和青少年患者的新药上市申请。在部分罕见肿瘤中，例如唾液腺癌、分泌型乳腺癌、婴儿纤维肉瘤等，发生率超过90%。福泰制药小核酸药物探索神经肌肉疾病近日，福泰制药在ClinicalTrials网站登记一项Ⅱ期临床试验，评估VX-670对Ⅰ型强直性肌营养不良症患者的长期安全性和耐受性、疗效和药代动力学。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416183133a45afd98&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416183133a45afd98&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","LU1093756325.SGD","LU2362540622.SGD","LU0289739699.SGD","LU1430594728.SGD","LU0823416689.USD","VRTX","LU0079474960.USD","LU0061475181.USD","IE00BFTCPJ56.SGD","LU1035775433.USD","SG9999013999.USD","LU2362541273.HKD","LU1585245621.USD","LU2237438978.USD","LU0109394709.USD","SGXZ57979304.SGD","IE0002270589.USD","BK4532","IE00B894F039.SGD","LU2236285917.USD","LU2462157665.USD","BK4533","LU2456880835.USD","IE00BJJMRZ35.SGD","SG9999001176.SGD","IE00B2B36J28.USD","LU2362541513.USD","IE00B19Z3B42.SGD","LU0889565916.HKD","IE00BZ9MQY76.HKD","LU0320765992.SGD","BK4588","IE0002141913.USD","LU1069344957.HKD","IE00B19Z3581.USD","LU0058720904.USD","LU0417517546.SGD","IE00BJT1NW94.SGD","IE00B4R5TH58.HKD","LU1093756168.USD","LU2417539215.USD","BK4585","BK4139","SG9999001176.USD","IE0009355771.USD","LU2324357040.USD","IE00B19Z9P08.USD","LU0234570918.USD","IE00B19Z9Z06.USD","LU0256863811.USD"],"gpt_icon":0},{"id":"2527281437","title":"诺诚健华盘中异动 早盘股价大跌5.05%报8.090港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527281437","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527281437?lang=zh_cn&edition=full","pubTime":"2025-04-16 11:16","pubTimestamp":1744773393,"startTime":"0","endTime":"0","summary":"2025年04月16日早盘11时16分，诺诚健华股票出现波动，股价大幅下跌5.05%。截至发稿，该股报8.090港元/股，成交量306.8万股，换手率0.21%，振幅4.11%。资金方面，该股资金流入1061.21万港元，流出1169.32万港元。诺诚健华股票所在的生物技术行业中，整体跌幅为3.90%。该信息摘要如下：诺诚健华2024年财报显示，公司实现营业收入10.09亿元，同比增长36.68%，但归母净利润仍亏损4.41亿元，较上年同期收窄30.20%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416111634aa2c70d1&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250416111634aa2c70d1&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["688428","09969","BK0239"],"gpt_icon":0},{"id":"2527914156","title":"诺诚健华04月14日获主力加仓356万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2527914156","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2527914156?lang=zh_cn&edition=full","pubTime":"2025-04-14 16:17","pubTimestamp":1744618646,"startTime":"0","endTime":"0","summary":"04月14日, 诺诚健华股价涨2.61%，报收8.64元，成交金额1.26亿元，换手率0.97%，振幅5.11%，量比1.07。诺诚健华今日主力资金净流入356万元，上一交易日主力净流入102万元。该股近5个交易日上涨13.32%，主力资金累计净流入902万元；近20日主力资金累计净流入2618万元，其中净流入天数为14日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171649a4584d8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250414171649a4584d8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2518371370","title":"诺诚健华03月11日遭主力抛售5万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2518371370","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518371370?lang=zh_cn&edition=full","pubTime":"2025-03-11 16:15","pubTimestamp":1741680910,"startTime":"0","endTime":"0","summary":"03月11日, 诺诚健华股价跌2.04%，报收9.11元，成交金额9205万元，换手率0.68%，振幅5.16%，量比0.90。诺诚健华今日主力资金净流出5万元，上一交易日主力净流出270万元。该股近5个交易日下跌3.18%，主力资金累计净流入503万元；近20日主力资金累计净流入8934万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165247abf60670&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250311165247abf60670&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2518239212","title":"诺诚健华03月10日主力净流出270万元 散户资金买入","url":"https://stock-news.laohu8.com/highlight/detail?id=2518239212","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518239212?lang=zh_cn&edition=full","pubTime":"2025-03-10 16:17","pubTimestamp":1741594639,"startTime":"0","endTime":"0","summary":"03月10日, 诺诚健华股价跌4.62%，报收9.30元，成交金额1.22亿元，换手率0.87%，振幅11.59%，量比1.05。诺诚健华今日主力资金净流出270万元，上一交易日主力净流入427万元。该股近5个交易日上涨0.32%，主力资金累计净流入573万元；近20日主力资金累计净流入8898万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170824a269be38&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310170824a269be38&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2518262259","title":"诺诚健华盘中异动 下午盘股价大跌5.03%","url":"https://stock-news.laohu8.com/highlight/detail?id=2518262259","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518262259?lang=zh_cn&edition=full","pubTime":"2025-03-10 14:04","pubTimestamp":1741586662,"startTime":"0","endTime":"0","summary":"2025年03月10日下午盘14时04分，诺诚健华股票出现波动，股价快速下挫5.03%。截至发稿，该股报9.260港元/股，成交量555.675万股，换手率0.37%，振幅9.64%。资金方面，该股资金流入2240.04万港元，流出2246.27万港元。机构评级方面，在所有10家参与评级的机构中，90%的券商给予买入建议，10%的券商给予持有建议，无券商给予卖出建议。诺诚健华股票所在的生物技术行业中，整体跌幅为2.28%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310140422963fc183&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250310140422963fc183&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK0239","688428","09969"],"gpt_icon":0},{"id":"2518923180","title":"智通港股早知道 | 港股今年日均成交额超2000亿港元 3月组件排产提升显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2518923180","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518923180?lang=zh_cn&edition=full","pubTime":"2025-03-10 06:59","pubTimestamp":1741561142,"startTime":"0","endTime":"0","summary":"陈翊庭：港股今年以来日均成交额超2000亿港元港交所行政总裁陈翊庭9日表示，港股今年以来日均成交额超2000亿港元。陈翊庭说，港股成交额在过去一年也有很大进步，由2023年平均每日成交额大约1000亿港元升至去年的1320亿港元，今年暂时已突破2000亿港元。她说，今年2月，港股每日成交金额有3次突破4000亿港元，其中很大部分来自世界各地的投资者。涉及港股 港交所及优质券商板块。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259508.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09969","YANG","HSTECH","01208","02410","BK1227","BK1592","BK1190","BK1594","HSCEI","BK1574","BK1161","BK4614"],"gpt_icon":1},{"id":"2518407366","title":"诺诚健华:ICP-488用于治疗中重度斑块状银屑病疗效显著","url":"https://stock-news.laohu8.com/highlight/detail?id=2518407366","media":"格隆汇","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518407366?lang=zh_cn&edition=full","pubTime":"2025-03-09 19:27","pubTimestamp":1741519625,"startTime":"0","endTime":"0","summary":"格隆汇3月9日丨诺诚健华公布，CP-488用于治疗中重度斑块状银屑病的II 期研究数据已于2025年美国皮肤病学会年会上公布，该学会是皮肤科领域最具影响力的国际盛会，相关数据以重磅口头报告形式发表。研究结果表明，ICP-488在每天一次6毫克和每天一次9毫克的剂量下对银屑病患者均具有显著疗效，且展现出良好的安全性和耐受性，为中重度银屑病患者提供了有价值的治疗选择。请读者仅作参考，并请自行承担全部责任。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309193145963f0bdd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250309193145963f0bdd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2518085401","title":"诺诚健华报告新药ICP-488银屑病临床试验数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2518085401","media":"财中社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518085401?lang=zh_cn&edition=full","pubTime":"2025-03-09 18:14","pubTimestamp":1741515240,"startTime":"0","endTime":"0","summary":"3月9日，诺诚健华发布公告，近日公司在2025年美国皮肤病学会年会上以重磅口头报告的形式，介绍了关于治疗银屑病的新药ICP-488的临床试验数据。研究结果显示，ICP-488在每天一次6毫克和9毫克的剂量下，均对银屑病患者展现出显著疗效，并且具有良好的安全性和耐受性。治疗期间出现的不良事件均为轻度或中度，未对患者造成重大影响。2024年前三季度，诺诚健华实现收入6.98亿元，归母净利润-2.75亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030918230398a16aa2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025030918230398a16aa2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1583","BK1161","03347","688428","BK1576","BK1141","09969"],"gpt_icon":0},{"id":"2518441401","title":"诺诚健华(09969)：ICP-488用于治疗中重度斑块状银屑病疗效显著 且展现出良好的安全性和耐受性","url":"https://stock-news.laohu8.com/highlight/detail?id=2518441401","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518441401?lang=zh_cn&edition=full","pubTime":"2025-03-09 18:12","pubTimestamp":1741515148,"startTime":"0","endTime":"0","summary":"智通财经APP讯，诺诚健华(09969)公布，CP-488用于治疗中重度斑块状银屑病的II 期研究数据已于2025年美国皮肤病学会(AAD)年会上公布，该学会是皮肤科领域最具影响力的国际盛会，相关数据以重磅口头报告形式发表。研究结果表明，ICP-488在每天一次(QD)6毫克和每天一次9毫克的剂量下对银屑病患者均具有显著疗效，且展现出良好的安全性和耐受性，为中重度银屑病患者提供了有价值的治疗选择。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1259489.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","09969","BK1574","688428","BK0239"],"gpt_icon":0},{"id":"2518709403","title":"诺诚健华：ICP-488治疗银屑病数据在AAD年会上以口头报告发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2518709403","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518709403?lang=zh_cn&edition=full","pubTime":"2025-03-09 16:01","pubTimestamp":1741507279,"startTime":"0","endTime":"0","summary":"诺诚健华(688428.SH)公告称，近日，公司在2025年美国皮肤病学会（AAD）年会上以重磅口头报告的形式，发布了标题为《高选择性口服TYK2抑制剂ICP-488治疗中重度斑块状银屑病的疗效和安全性：一项随机双盲安慰剂对照II期临床试验》的报告。研究结果表明，ICP-488在每天一次（QD）6毫克和每天一次9毫克的剂量下对银屑病患者均具有显著疗效，且展现出良好的安全性和耐受性，为中重度银屑病患者提供了有价值的治疗选择。以上内容为证券之星据公开信息整理，由智能算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025030900002496.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09969","BK0239","688428","BK1574","BK1161"],"gpt_icon":0},{"id":"2518035414","title":"【诺诚健华：ICP-488 治疗银屑病数据在 2025 年 AAD 年会重磅发布】金融界3月9日消息，诺诚健华在 2025 年美国皮肤病学会年会以重磅口头报告形式发布了关于高选择性口服 TYK2 抑制剂 ICP-488 治疗中重度斑块状银屑病的疗效和安全性报告。129 例患者按 1:1:1 比例随机分三组接受 12 周治疗。第 12 周时，6 毫克和 9 毫克剂量组的 PASI 75 应答率分别为 77.3%和 78.6%，PASI 90 应答率分别达 36.4%和 50.0%，sPGA 0/1 应答率分别为 70.5%和 71.4%，均显著高于安慰剂组。治疗期间不良事件均为轻度或中度。新药研发具风险，本次临床数据对当前业绩无重大影响。","url":"https://stock-news.laohu8.com/highlight/detail?id=2518035414","media":"金融界","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2518035414?lang=zh_cn&edition=full","pubTime":"2025-03-09 15:45","pubTimestamp":1741506344,"startTime":"0","endTime":"0","summary":"金融界3月9日消息，诺诚健华在 2025 年美国皮肤病学会年会以重磅口头报告形式发布了关于高选择性口服 TYK2 抑制剂 ICP-488 治疗中重度斑块状银屑病的疗效和安全性报告。129 例患者按 1:1:1 比例随机分三组接受 12 周治疗。第 12 周时，6 毫克和 9 毫克剂量组的 PASI 75 应答率分别为 77.3%和 78.6%，PASI 90 应答率分别达 36.4%和 50.0%，sPGA 0/1 应答率分别为 70.5%和 71.4%，均显著高于安慰剂组。治疗期间不良事件均为轻度或中度。新药研发具风险，本次临床数据对当前业绩无重大影响。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://24h.jrj.com.cn/2025/03/09154548614660.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"jinrongjie_stock","symbols":["BK1574","09969","BK1161","688428","BK0239"],"gpt_icon":0},{"id":"2517964754","title":"诺诚健华联合创始人、董事长兼CEO崔霁松：医药企业需要建立预见变革与抵御风险的双重能力","url":"https://stock-news.laohu8.com/highlight/detail?id=2517964754","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517964754?lang=zh_cn&edition=full","pubTime":"2025-03-08 09:44","pubTimestamp":1741398270,"startTime":"0","endTime":"0","summary":"“2025年是诺诚健华发展进程的第十年，我在创办诺诚健华以来遇到的困难是我前面所有职业生涯加起来的总和。”说这句话的，是诺诚健华联合创始人、董事长兼CEO崔霁松。在男性占比更高的商业世界，她是性别上的“少数”，但在技术日新月异的医药行业，崔霁松的职业生涯从Merck书写至BioDuro，再到自立门户加入国产创新药自研浪潮，其已是行业佼佼者。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202503083340319431.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202503083340319431.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["09969","BK1574","BK1161"],"gpt_icon":0},{"id":"2517105903","title":"诺诚健华03月07日获主力加仓427万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517105903","media":"市场透视","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517105903?lang=zh_cn&edition=full","pubTime":"2025-03-07 16:16","pubTimestamp":1741335385,"startTime":"0","endTime":"0","summary":"03月07日, 诺诚健华股价涨0.83%，报收9.75元，成交金额8695万元，换手率0.59%，振幅6.00%，量比0.56。诺诚健华今日主力资金净流入427万元，连续4日净流入，上一交易日主力净流入225万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为25.00%，平均涨幅为2.86%。该股近5个交易日上涨5.86%，主力资金累计净流入185万元；近20日主力资金累计净流入9018万元，其中净流入天数为13日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170530a263de72&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250307170530a263de72&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2517139365","title":"诺诚健华03月06日获主力加仓225万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517139365","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517139365?lang=zh_cn&edition=full","pubTime":"2025-03-06 16:15","pubTimestamp":1741248947,"startTime":"0","endTime":"0","summary":"03月06日, 诺诚健华股价涨1.79%，报收9.67元，成交金额1.08亿元，换手率0.74%，振幅5.16%，量比0.49。诺诚健华今日主力资金净流入225万元，连续3日净流入，上一交易日主力净流入124万元。近一年数据显示，该股主力连续3日净流入后，次日上涨概率为53.85%，平均涨幅为2.69%。该股近5个交易日下跌0.21%，主力资金累计净流出682万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入8586万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165417a26228bd&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250306165417a26228bd&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","09969","BK1161"],"gpt_icon":0},{"id":"2517995470","title":"诺诚健华03月05日获主力加仓124万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2517995470","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517995470?lang=zh_cn&edition=full","pubTime":"2025-03-05 16:15","pubTimestamp":1741162546,"startTime":"0","endTime":"0","summary":"03月05日, 诺诚健华股价涨0.64%，报收9.50元，成交金额1.31亿元，换手率0.91%，振幅9.64%，量比0.51。诺诚健华今日主力资金净流入124万元，上一交易日主力净流入65万元。该股近5个交易日上涨4.80%，主力资金累计净流入1107万元，其中1个交易日为股价下跌时净流入；近20日主力资金累计净流入8489万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305165947a26058f4&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305165947a26058f4&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1161","BK1574","09969"],"gpt_icon":0},{"id":"2517930861","title":"诺诚健华盘中异动 股价大涨5.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2517930861","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2517930861?lang=zh_cn&edition=full","pubTime":"2025-03-05 10:13","pubTimestamp":1741140825,"startTime":"0","endTime":"0","summary":"2025年03月05日早盘10时13分，诺诚健华股票出现波动，股价大幅拉升5.19%。截至发稿，该股报9.930港元/股，成交量390.3万股，换手率0.26%，振幅5.51%。资金方面，该股资金流入2152.37万港元，流出986.321万港元。机构评级方面，在所有9家参与评级的机构中，100%的券商给予买入建议，无券商给予持有、卖出建议。诺诚健华股票所在的生物技术行业中，整体涨幅为0.63%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305101345989c6b8b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250305101345989c6b8b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09969","BK0239","688428"],"gpt_icon":0},{"id":"2516625790","title":"诺诚健华03月04日主力净流入65万元 散户资金抛售","url":"https://stock-news.laohu8.com/highlight/detail?id=2516625790","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2516625790?lang=zh_cn&edition=full","pubTime":"2025-03-04 17:39","pubTimestamp":1741081187,"startTime":"0","endTime":"0","summary":"03月04日, 诺诚健华股价涨1.18%，报收9.44元，成交金额8867万元，换手率0.64%，振幅5.68%，量比0.34。诺诚健华今日主力资金净流入65万元，上一交易日主力净流出658万元。该股近5个交易日上涨20.03%，主力资金累计净流入3729万元；近20日主力资金累计净流入8525万元，其中净流入天数为12日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174956a25ea7ae&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20250304174956a25ea7ae&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1574","BK1161","09969"],"gpt_icon":0}],"profile":{"websiteUrl":"https://cn.innocarepharma.com","stockEarnings":[{"period":"1week","weight":0.0455},{"period":"1month","weight":-0.0862},{"period":"3month","weight":0.5752},{"period":"6month","weight":0.1968},{"period":"1year","weight":0.8176},{"period":"ytd","weight":0.3513}],"compareEarnings":[{"period":"1week","weight":0.0391},{"period":"1month","weight":-0.1279},{"period":"3month","weight":0.0786},{"period":"6month","weight":0.0122},{"period":"1year","weight":0.2959},{"period":"ytd","weight":0.0497}],"compareStock":{"symbol":"HSI","name":"恒生指数"},"description":"诺诚健华医药有限公司是一家主要从事生物医药研发、生产和商业化的中国公司。该公司专注于肿瘤和自身免疫性疾病等存在巨大未满足临床需求的领域。该公司的主要产品管线包括奥布替尼、Tafasitamab、ICP-490、ICP-B02、ICP-248、ICP-B05、ICP-332、ICP-488、ICP-192、ICP-723、ICP-033和ICP-189等。其产品主要用于治疗血液瘤、实体瘤和自身免疫病。该公司还在开发用于治疗由B细胞或T细胞功能异常所导致的自身免疫性疾病的产品。该公司主要在国内和国外市场开展业务。","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.115368},{"month":2,"riseRate":0.6,"avgChangeRate":0.148393},{"month":3,"riseRate":0,"avgChangeRate":-0.036551},{"month":4,"riseRate":0.5,"avgChangeRate":0.081759},{"month":5,"riseRate":0,"avgChangeRate":-0.072765},{"month":6,"riseRate":0.8,"avgChangeRate":0.122586},{"month":7,"riseRate":0.4,"avgChangeRate":-0.028005},{"month":8,"riseRate":0.2,"avgChangeRate":-0.086099},{"month":9,"riseRate":0.2,"avgChangeRate":-0.051427},{"month":10,"riseRate":0.4,"avgChangeRate":0.007797},{"month":11,"riseRate":0.8,"avgChangeRate":0.112999},{"month":12,"riseRate":0.6,"avgChangeRate":0.018835}],"exchange":"SEHK","name":"诺诚健华","nameEN":"INNOCARE"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.33.1","shortVersion":"4.33.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"诺诚健华,09969,诺诚健华股票,诺诚健华股票老虎,诺诚健华股票老虎国际,诺诚健华行情,诺诚健华股票行情,诺诚健华股价,诺诚健华股市,诺诚健华股票价格,诺诚健华股票交易,诺诚健华股票购买,诺诚健华股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"诺诚健华(09969)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供诺诚健华(09969)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}